Gland pharma Limited has announced a significant addition to its senior management team with the appointment of Dr. Jitendra Gangwal as Vice-President (Research and Development), effective February 18, 2026. The pharmaceutical company made this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Leadership Appointment Details

The appointment represents a strategic move to strengthen the company's research and development capabilities. Dr. Gangwal assumes his role as a Senior Management Personnel of the company, bringing extensive expertise in pharmaceutical R&D operations.

Professional Background and Expertise

Dr. Jitendra Gangwal brings over 24 years of progressive experience in pharmaceutical research and development across premier research institutions and leading Indian pharmaceutical organizations. His career trajectory demonstrates steady growth from scientific research roles to executive leadership positions in formulation R&D.

Key Professional Achievements

Throughout his distinguished career, Dr. Gangwal has made significant contributions to pharmaceutical development:

Technical Specializations

Dr. Gangwal's expertise spans a comprehensive range of advanced pharmaceutical technologies and delivery systems:

• Complex parenterals and injection formulations
• Ophthalmic, inhalation, and nasal delivery systems
• Oral route formulations
• Advanced delivery technologies including nano-crystals, liposomes, and microspheres
• Depot systems and peptide formulations
• Metal complexes and polymer-based delivery systems

Career History and Educational Background

Prior to joining Gland Pharma Limited, Dr. Gangwal has been associated with several prestigious organizations in the pharmaceutical and research sectors. His professional journey includes tenure at National Chemical Laboratory (NCL) in Pune, Dr. Reddy's Laboratories Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, and FDC Limited.

Dr. Gangwal holds a PhD from National Chemical Laboratory, Pune, providing him with a strong foundation in pharmaceutical sciences and research methodologies. His academic credentials complement his extensive industry experience, positioning him to drive innovation and strategic development initiatives.

Strategic Impact

The appointment reflects Gland Pharma's commitment to strengthening its research and development capabilities under experienced leadership. Dr. Gangwal combines deep scientific expertise with strategic business acumen, regulatory insight, and proven leadership capabilities to deliver high-value, commercially viable complex products in regulated global markets.

His extensive experience in developing complex pharmaceutical products and establishing R&D infrastructure positions him to contribute significantly to the company's innovation pipeline and regulatory compliance objectives in the competitive pharmaceutical landscape.

Gland Pharma Limited has secured regulatory approval from the United States Food and Drug Administration (USFDA) for its Zoledronic Acid injection, marking a significant milestone in the company's oncology portfolio expansion. The approval was formally communicated to stock exchanges under Regulation 30 of SEBI listing requirements.

Product Specifications and Regulatory Details

The company received approval for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid injection with specific formulation parameters:

Expanded Therapeutic Applications

The approved injection addresses three critical cancer-related conditions, representing an expansion from the initially projected two indications. The product is indicated for treating:

• Hypercalcemia of Malignancy
• Multiple Myeloma
• Bone Metastases of Solid Tumors

This broader therapeutic scope enhances the product's market potential and clinical utility in oncology care, providing healthcare providers with treatment options for various cancer-related bone complications.

Market Performance Data

According to IQVIA data, the market performance for this product category shows established commercial activity:

Regulatory Compliance and Communication

Gland Pharma formally notified both major Indian stock exchanges about this development in compliance with regulatory requirements. The company communicated the approval to BSE Limited (Scrip Code: 543245) and National Stock Exchange of India Limited (Symbol: GLAND, ISIN: INE068V01023) under Regulation 30 of SEBI listing obligations.

Strategic Market Position

This USFDA approval strengthens Gland Pharma's position as a leading injectable-focused pharmaceutical company with global operations across 60 countries. The company, established in 1978 and headquartered in Hyderabad, has evolved from a contract manufacturer to become one of the largest injectable-focused companies globally, operating primarily under a business-to-business model with expertise in sterile injectables including vials, ampoules, pre-filled syringes, and oncology solutions.